Innate Pharma Announces Phase Iia Results with IPH 1101 as Second Line Monotherapy in Metastatic Renal Cell Carcinoma
· Primary efficacy endpoint not reached
· Secondary endpoints reached: very good safety profile and robust dose-dependent ?? T cell amplification
· Other Phase I/II and IIa trials in cancer ongoing
MARSEILLES, France, May 23, 2008 - Innate Pharma, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma (“mRCC”). Whereas the primary efficacy endpoint, progression-free survival rate at 12 weeks, was not reached, the product was well tolerated and triggered a robust pharmacodynamic effect, confirming the dosage chosen for other clinical trials.
“The results of this Phase IIa study show a strong pharmacodynamic effect in terms of gamma delta T cell amplification and the regimen is associated with a very good safety profile” said Pr. Bernard Escudier, coordinating investigator of the study. He added: “Although the observed anti-tumor activity is not sufficient to support further development in advanced mRCC in monotherapy, these results warrant testing the activity of the drug candidate in other, more favorable, indications and regimens.”
Hervé Brailly, CEO of Innate Pharma, added: “The confirmation of the good safety profile and of the robust pharmacodynamic effect is an important step in the development of IPH 1101. We are confident in the development of the product. The Phase IIa exploratory program is ongoing, and first efficacy data in other indications and combination regimens should be obtained by the end of 2009. Those data will be the basis for the future development and potential business partnering for this drug candidate.”
Conference call: Innate Pharma management will be hosting a
conference call to discuss these results today, at 10 am (Paris
time) in French and at 11 am (Paris time) in English. Investors,
journalists and financial analysts are invited to participate in
the conference call by dialing +33 (0)1 72 28 25 82 for the
conference in French and +33 (0)1 72 28 25 87 for the conference in
English.
Posted: May 2008
